Any person diagnosed
with cancer or any medical practitioner intimate with the study of this disease
has learned that one of the most critical pieces of data for determining
prognosis is the stage the cancer is in when first discovered. The more
advanced the cancer stage at diagnosis, the lower the survival rate. The
earlier the stage when discovered, the greater the chances of survival. To
simply state, ‘the earlier the better,’ could easily be called as the
understatement of the century. Our inquiring minds beg for answers to logical
questions preceded with, ‘If only…’ or ‘What if there were a way…’
Zenosense Inc.
(OTCQB: ZENO) is a company that not only asks, ‘What if,’ they are a company
that devotes its time, attention and resources on producing an answer.
Specifically, ZENO is committed to developing a non-invasive, cost-effective
early detection screening method for detecting lung cancer. Long term,
shareholder value intentions are believed to offer noticeable improvements in
survival and mortality rates.
The company operates
on the cutting edge of executing on the challenge of developing practical,
cost-effective medical devices that will detect at the earliest of stages,
deadly lung cancer bacteria and other cancers in a patient’s exhaled breath. And
as would be expected, the promising news coming from company development
efforts is generating positive activity and excitement.
In November of 2014,
ZENO announced plans to manufacture a pre-market prototype device that would be
evaluated during a lung cancer detection trial in a clinical setting. Zenon
Biosystem, Zenosense’s development partner, assumed a leadership position in a
project that would be responsible for manufacturing the prototype. In
preparation for the planned trial and to meet the standards of the trial’s
protocol design, Zenon planned to manufacture two pre-commercial devices of
identical design to ensure that trial results could be duplicated. A month
later, Zenon announced that it would be collaborating with a university and a
large university hospital in Madrid, Spain on a nine month long lung cancer
detection trial that will facilitate clinical tests on breath samples from 400
people.
Zenosense feels that
a cost-effective, breath-analyzing lung cancer detector that is proven to meet
or exceed the accuracy of low-dose Computed Tomography (CT) scanning will have
broad appeal and demand. As a result, company development efforts have welcomed
the news that a team of university research scientists and their hospital have
recognized the potential for the technology. A positive outcome from the
planned lung cancer detection trial will be a significant step toward a major
healthcare breakthrough and quite possibly provide a much needed answer to the
question, ‘What if…’
For more information
on the company, visit www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment